Ontology highlight
ABSTRACT: Introduction
Medulloblastoma is the most common and lethal pediatric malignant brain tumor. It comprises four main molecular subgroups: WNT-activated, SHH-activated, Group 3, and Group 4. Medulloblastoma treatment is surgical resection, craniospinal radiation, and chemotherapy. However, many patients do not respond to therapy, and most suffer severe side effects. Cancer immunotherapy targeting immune checkpoints (IC) (PD-1, PD-L1, and CTLA4) has been getting disappointing outcomes in brain tumors. Nevertheless, other less explored immune checkpoints may be promising candidates for medulloblastoma therapy.Objectives
In the present study, we aimed to characterize the expression profile of 19 immune checkpoints in medulloblastoma.Methods
We analyzed 88 formalin-fixed p
SUBMITTER: Marques RF
PROVIDER: S-EPMC9941636 | biostudies-literature | 2023
REPOSITORIES: biostudies-literature